Mirion Technologies, Inc. Class A (MIR)
Live price chart, market sentiment, and community perspectives for Mirion Technologies, Inc. Class A (NYSE: MIR).
Live price chart, market sentiment, and community perspectives for Mirion Technologies, Inc. Class A (NYSE: MIR).
On our desk, the valuation debate on Mirion is getting heated. While the headline Q2 revenue growth of 19.7% and Adjusted EBITDA jumping 27.5% to $65.3 million look phenomenal against the AI-powered nuclear energy narrative, the trailing P/E sitting north of 160x makes me uncomfortable. We are seeing a stark divergence between fundamental operational tailwinds—like the 40% jump in total orders including the Paragon and Certrec acquisitions—and technical alerts warning of an active breakdown. If you are entering here around the $15.65 to $16.59 range, you are paying a massive premium expecting flawless execution.
Looking at the Q2 2026 10-Q filing details, the debt-to-equity ratio remains relatively tame at 0.2, and the balance sheet shows 243.3 million Class A shares outstanding. However, GAAP net income dipped 4.7% YoY to $8.1 million, translating to a GAAP EPS of just $0.03 for the quarter. While Adjusted EPS came in at $0.12, the discrepancy driven by stock-based compensation and acquisition adjustments demands careful scrutiny. Risk parameters from quantitative models indicate that a failure to hold immediate support could trigger further downward drift, making strict stop-loss discipline essential.
From a technical and tactical positioning angle, our quantitative models highlight choppy conditions and divergent sentiment horizons for MIR. While some analysts maintain a $25 price target implying heavy upside, our current reading shows a breakdown underway with limited long-term support signals remaining below current trading levels. Position traders looking at long setups in the $17.63 entry zone must respect tight risk parameters—like a stop loss at $17.68—given the lack of structural cushion beneath the current price action.
Explore plasma cleansing, somatic organ swaps, and BCI.